A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy

Kidney Int. 2018 Oct;94(4):788-794. doi: 10.1016/j.kint.2018.05.021. Epub 2018 Jul 23.


One of the most difficult management issues in lupus nephritis (LN) is the optimal duration of maintenance immunosuppression after patients are in clinical remission. Most patients receive immunosuppression for years, based mainly on expert opinion. Prospective data are unavailable. Complicating this issue are data that patients in clinical remission can still have histologically active LN; however, the implications of this are unknown. To study this, the Lupus Flares and Histological Renal Activity at the end of Treatment study (ClinicalTrial.gov, NCT02313974) was designed to examine whether residual histologic activity predisposes to LN flares in class III and IV LN. Patients in complete clinical remission for at least 12 months who had received at least 36 months of immunosuppression were eligible. Patients consented to a second kidney biopsy, were tapered off maintenance immunosuppression and were then followed prospectively for LN flares over 24 months. Forty-four patients were enrolled, and 36 completed the study. LN flares occurred in 11 patients, and ten of these had residual histologic activity on the second biopsy. All patients with an NIH activity index over two flared. The activity index and duration of systemic lupus erythematosus at the second biopsy were independent predictors of flare. A predictive equation based on these variables discriminated between flare and no flare with a sensitivity of 100%, specificity of 88%, and a misclassification rate of 8.3%. Thus, a repeat kidney biopsy may be useful in managing maintenance immunosuppression in LN, and patients in histologic remission may be candidates for withdrawal of therapy.

Keywords: histologic activity; kidney biopsy; lupus nephritis; renal flare; systemic lupus erythematosus.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Biopsy
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney / pathology*
  • Lupus Nephritis / drug therapy*
  • Lupus Nephritis / pathology*
  • Maintenance Chemotherapy
  • Male
  • Prospective Studies
  • Remission Induction
  • Risk Assessment / methods
  • Risk Factors
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Symptom Flare Up*
  • Withholding Treatment
  • Young Adult


  • Immunosuppressive Agents

Associated data

  • ClinicalTrials.gov/NCT02313974